Physician profile

John B Dalton

Internal Medicine · Long Branch, NJ

NPI 1629041231

$1,736.71

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $390.94 2019-2022
Merck Sharp & Dohme LLC $285.27 2019-2022
Glaxosmithkline, LLC. $267.53 2020-2022
Amarin Pharma, INC. $125.16 2019-2021
Astrazeneca Pharmaceuticals LP $101.23 2019-2020
Pfizer INC. $95.18 2019-2022
Abbott Laboratories $87.39 2020-2021
Abbvie INC. $86.13 2021-2022
Lilly USA, LLC $51.52 2019-2022
Janssen Pharmaceuticals, INC $50.99 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $44.57 2019-2022
Sanofi Pasteur INC. $24.28 2019-2020
Biohaven Pharmaceuticals, INC. $20.39 2021
Biohaven Pharmaceutical Holding Company LTD. $14.93 2022
Novartis Pharmaceuticals Corporation $14.44 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Genentech USA, INC. $13.86 2022
Horizon Therapeutics Plc $13.03 2022
Xeris Pharmaceuticals, INC. $12.78 2022
Ironwood Pharmaceuticals, INC $12.77 2020
Kowa Pharmaceuticals America, INC. $12.59 2022
Allergan, INC. $11.73 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John B Dalton

$1,736.71

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/751403/john-b-dalton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.